A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY
Phase of Trial: Phase IV
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MuSicalE
- Sponsors Roche
- 05 Nov 2019 Planned number of patients changed from 1000 to 1250.
- 05 Nov 2018 Planned End Date changed from 1 Jul 2025 to 18 Jul 2025.
- 05 Nov 2018 Planned primary completion date changed from 1 Jul 2025 to 18 Jul 2025.